
A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a consumer-reported vial.

A single lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, is being voluntarily recalled by Alcon Laboratories due to the detection of fungal material in a consumer-reported vial.

This action follows a consumer complaint of foreign material in a sealed single-use vial.

Look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Trending topics and milestone stories from 2024 on Ophthalmology Times Europe

A team of researchers in China detail a case of Thelazia callipaeda infection in the right eye of a 41-year-old woman working in an office. The patient presented with persistent foreign body sensation, pruritus, and redness despite initial treatment with polyethylene glycol and levofloxacin eye drops.


The top therapeutic advancements in myopia, diabetes, dry eye and more

A look at the biggest news and advancements in ophthalmology in 2024.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet stripping only (DSO). Long-term outcomes show promising results, supporting DSO as a viable alternative to traditional donor-tissue-based keratoplasty procedures.

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 inhibitor therapy.

Options empower patients and providers to decrease treatment burden.

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual function in optic neuropathy patients. Clinical trials show promising results in visual field improvements, though further research is needed on long-term efficacy and quality of life.

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's Journal Club, highlighting a 77% success rate at 5 years and evolving techniques.

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty discussions on ophthalmology research to enhance clinical practice and trainee education.

Trending topics and milestone stories from our year in ophthalmology

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.


Did you miss any of our print issues this year? Don’t worry, they are still available online.

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.

Enhancing durability and reducing treatment burden.

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.


Our top 10 print stories highlight the core content concepts we explored this year


This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.
